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Evaluation of a macrophage attenuated isolate of'PRRSV as a 
vaccine for porcine reproductive and respiratory syndrome virus 
C.D. Nelson, R.R. Rowland, D.H. Zeman and D.A. Benfield 
Department of Veterinary Science 
SDSU SWINE 2001-19 
PRRS continues to be the most 
economically important disease of swine. While 
the acute reproductive disease is still prevalent, 
chronic or endemic PRRS in nursery and 
grow/finish pigs is a major problem confronting 
most swine producers. Post-weaning problems 
in these herds include a 50-85% reduction in 
growth rates; a 10-30% increase in 
unmarketable pigs; and a 10-25% increase in 
post-weaning mortality. Popular protocols .to 
manage PRRSV infections include breeding 
herd stabilization; elimination of seronegative 
sub-populations of susceptible gilts; nursery 
depopulation; and more recently mass 
vaccination/unidirectional pig flow in the 
grow/finish unit. Most of these control programs 
also use the commercial modified-live vaccines, 
RespPRRS® or PrimePac PRRS® as part of the 
management protocol. 
Although modified-live PRRSV vaccines are 
useful management tools, producers and 
veterinarians are mindful of their undesirable 
traits and disadvantages, which include: 
induction of viremia; infection of fetuses in 
vaccinated pregnant animals; transmission of 
vaccine virus to naive pigs; persistence of 
vaccine virus in pigs; shedding of vaccine virus 
in semen; and the potential for vaccine virus to 
revert to virulence. These problems explain the 
recent popularity of using autogenous and 
commercial (PRRomi~e ™) killed vaccines, which 
are safer than modified-live vaccines. However, 
many of the problems •inherent to modified-live 
PRRSV vaccines are related to the ability of 
vaccine viruses to imitate virulent field viruses 
and replicate in macrophages, which results in: 
1) dissemination of the virus in the pig; 
2) shedding through bodily secretions; 
3) transplacental transmission; and 
4) persistence in lymphoid tissue. Both 
RespPRRS® and PrimePac PRRS® replicate in 
pig alveolar macrophages and this may p;irtially 
explain why vaccinated pigs develop viremia 
and shed virus to contacts. It may also explain 
why the virus is able to reach the fetus in 
105 
pregnant animals. If replication in macrophages 
accounts for the undesirable traits of modified-
live PRRSV vaccines, then a vaccine virus that 
is "macrophage-attenuated" (reduced or no 
replication in macrophages) would be safer. 
This vaccine can be produced in the 
conventional fashion; would be more economical 
to produce than molecular or subunit vaccines, 
and would avoid the loss of structural antigens 
(antigenicity), which is a problem with subunit 
and killed vaccines. The purpose of this study 
was to test two PRRSV isolates that replicate 
poorly in porcine alveolar macrophages, for 
safety and efficacy in young pigs and pregnant 
animals. 
The goal of this project is to determine if an 
isolate of PRRSV, that has been modified by 
serial passage in monkey kidney cells (MARC-
145) and replicates at very low levels in porcine 
alveolar macrophages, is avirulent for pigs and 
pregnant gilts. The original aims were to 
determine if this macrophage-attenuated isolate 
replicates in neonatal pigs, induces viremia 
and/or lesions and results in seroconversion. 
Experimental Procedures 
Objective 1: Does the macrophage 
attenuated isolate of PRRSV 23983 replicate in 
neonatal pigs, induce viremia and/or lesions and 
cause seroconversion? The passage-136 
(P136) isolate of PRRSV 23983 does · not 
replicate well in alveolar macrophages, but does 
grow to high titers in the MARC-145 cells to 
which the virus is adapted. Thus, we compared 
the virulence of the parental wild-type virus 
passage-6 (P6) and the macrophage-attenuated 
P136 to the two commercial modified-live virus 
vaccines (RespPRRS® and PrimePac PRRS®). 
In these experiments, 58, 6-day old gnotobiotic 
pigs from three litters were inoculated either 
intranasally or intramuscularly with the P6, 
P136, commercial vaccines or mock inoculum. 
Each virus was adjusted to result in a dosage of 
104 tissue culture infectious doses (TCID50) per 
2 ml of inoculum. Piglets were observed daily 
for clinical signs and rectal temperatures were 
recorded for 14 days post inoculation (dpi) with 
virus. After 2 weeks, pigs were euthanized, 
examined at post-mortem for gross lesions and 
various tissues [lung, lymph nodes 
(trachealbronchial, mandibular, mesenteric, and 
external inguinal), salivary gland, heart, thymus, 
spleen, liver and tonsil] were removed for virus 
isolation and light microscopy examination for 
microscopic lesions. Serum was also collected 
at 0, 1, 3, 5, 7, 10 and 14 dpi for serology and 
virus isolation. 
Results 
Objective 1: Does the macrophage 
attenuated isolate of PRRSV 23983 replicate in 
neonatal pigs, induce viremia and/or lesions and 
cause seroconversion? Our goal was to 
determine if the loss of the ability of PRRSV to 
replicate in alveolar macrophages would result 
in a virus that is less virulent in pigs than the 
current modified-live vaccines (RespPRRS® and 
PrimePac PRRS®). Sequential passage of the 
23983 PRRSV on MARC-145 cells resulted in a 
reduction in the yield of PRRSV in alveolar 
macrophages. Fifty-four passages of the 
PRRSV resulted in only a 10-fold reduction in 
virus yield compared to the virulent PS. 
Similarly, there was a 100- and 1000-fold 
reduction in the yield of PRRSV from passages 
P94 and P136, respectively (Figure 1). 
Comparison of the virulence of the 
macrophage-attenuated P136 isolate to the 
virulent P6 isolate of the 23983 PRRSV and the 
commercial modified-live viral vaccines was 
done using 58 gnotobiotic pigs randomly 
assigned to experimental groups indicated in 
Table 1. Daily clinical scores varied within 
experimental groups. Surprisingly, the pigs 
given PrimePac PRRS® intranasally had the 
most severe clinical signs between 4 and 8 dpi, 
after which the P6 group had the most 
prominent clinical signs from 8 to 17 dpi. 
Clinical signs included lethargy, inappetance, 
diarrhea, eyelid edema and occasional 
lacrimation. Milder clinical signs were observed 
in the P136 pigs for the first 5 dpi. Clinical signs 
of lethargy and lacrimation were also observed 
in 2/10 mock-infected pigs. In general, the P136 
pigs had fewer and milder clinical signs of 
PRRSV compared to the other virus infected 
pigs. 
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There was no significant variation in daily 
temperatures between the inoculated groups of 
pigs. Temperatures were highest in the P6 
inoculated pigs between 7 to 14 dpi. The rectal 
temperatures in the P136 pigs tended to be 
similar to those of pigs given the modified-live 
vaccine viruses. 
Dyspnea (severe, labored breathing) was 
only observed in pigs receiving the P6 virulent 
isolate of PRRSV. This condition was principally 
observed from 10 to 18 dpi in pigs given P6 
intranasally and in a one pig at 15 dpi given the 
P6 intramuscularly. 
Pigs given the P6 PRRSV isolate had 
lesions typical of PRRS induced interstitial 
pneumonia in 9/10 animals and virus was 
isolated from all tissues sampled in 10/1 O pigs. 
Less severe lesions were observed in the lungs 
of 1/10 pigs inoculated with PrimePac PRRS® 
and 5/15 given RespPRRS®. Similar to the 
P6 inoculated pigs, vaccine virus was isolated 
from all pigs (10/10 and 13/13 pigs, 
respectively). In contrast, virus was only 
isolated from 1 /13 pigs given the macrophage-
attenuated isolate and none of these pigs had 
lesions. Two mock-inoculated pigs also had 
early clinical signs of lethargy and lacrimation. 
No lesions were observed and no virus was 
isolated from tissues of the mock-inoculated pigs 
(see Table 1 ). 
Seroconversion was monitored using the 
commercial enzyme-linked immunosorbent 
assay (ELISA) at O and 14 dpi. The pigs given 
the P6 inoculum either intranasally or intra-
muscularly all seroconverted by 14 dpi. In 
contrast, only 50% and 30% of the pigs given 
PrimePac PRRS® and RespPRRS® 
intramuscularly seroconverted by 14 dpi. A 
lower number of pigs receiving PrimePac 
PRRS® and RespPRRS® intranasally 
seroconverted at this time, 25% and 20%, 
respectively. None of the P136 or mock-
inoculated pigs was seropositive at 14 dpi. 
Significance of results from Obiective 1. 
The above results indicate that the P136 
macrophage-attenuated isolate is less virulent in 
pigs than either the P6 wild type or the 
commercial modified-live vaccine viruses. This 
is indicated by the less severe clinical signs, lack 
of febrile response and absence of lesions 
observed in pigs inoculated with the 
P136 PRRSV. The commercial vaccines did 
replicate extensively in the gnotobiotic pigs and 
virus was isolated from most tissues of these 
pigs regardless of the route of inoculation. 
However, the P136 virus was recovered from 
the lung of only one pig inoculated 
intramuscularly indicating that there is still rare 
potential for reversion to virulence of the P136 
isolate. There is probably less risk of 
transmission considering the lack of recoverable 
virus from tissues of the P136 pigs compared to 
the other virus isolates. Thus, these results 
indicate that macrophages do play a significant 
role in the pathogenesis of PRRSV and that a 
macrophage-attenuated isolate of PRRSV is 
less virulent in young pigs. It was disappointing 
that the P136 isolate did not result in 
seroconversion of the pigs at 14 dpi indicating 
that this attenuated virus may be too avirulent to 
induce an immune response. 
TABLE 1. SUMMARY OF RESULTS FOR GNOTOBIOTIC PIGS INOCULATED 
WITH P6, P136, RESPPRRS® AND PRIMEPAC PRRS® VIRUSES 
Number of Number of pigs Number of Number of pigs 
Route of pigs in with clinical pigs with lung positive for virus 
RRPS virus inoculation group disease lesions isolation (ELISA) 
P6 intranasal 5 5/5 5/5 5/5 (5/5) 
intramuscular 5 5/5 4/5 5/5 (5/5) 
P136 intranasal 6 1/6 0/6 0/6 (0/6) 
intramuscular 7 5/7 0/7 1/7 (0/7) 
Prime-Pac Intranasal 4 2/4 0/4 4/4 (1/4) 
intramuscular 6 6/6 1/6 6/6 (ND) 
RespPRRS intranasal 5 5/5 5/5 5/5 (1/5) 
intramuscular 10 6/10 0/10 10/10 (3/10) 
Mock intranasal 4 0/4 0/4 0/4 (0/4) 
intramuscular 6 2/6 1/6 0/6 (0/6) 
Numbers in parenthesis in the last column indicate the number of pigs positive for antibodies by 
ELISA/number of pigs inoculated with virus. 
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Figure 1. Replication of various passages of the 23983 PRRS virus on 
alveolar macrophages. Note that each successive passage of the virus in 
MARC-145 cells resulted in a reduction or attenuation of the virus yield in 
porcine alveolar macrophages. 
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